🔎 Trials Near Me

Dachaigh › Carcinoma Urothelial (Cealla Transitional) › Virginia

Sgrùdaidhean clionaigeach Carcinoma Urothelial (Cealla Transitional) ann an Virginia

Tha 21 sgrùdaidhean airson Carcinoma Urothelial (Cealla Transitional) a’ lorg phàirtichean aig làraichean ann an Virginia.

Bailtean ann an Virginia

Teacsa sgrùdaidh oifigeil (Beurla)

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

  • Inova Schar Cancer Institute, Fairfax
  • NEXT Virginia, Fairfax
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT06270706

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

  • Exelixis Clinical Site #66, Charlottesville
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 1 Dàmh 2026 · NCT05176483

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

  • Hematology Oncology Associates of Fredericksburg Inc, Fredericksburg
  • Virginia Cancer Institute, Richmond
  • VCU Massey Cancer Center at Stony Point, Richmond
  • agus 1 a bharrachd
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 1 Dàmh 2026 · NCT06524544

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

  • Virginia Oncology Associates, Norfolk
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 30 Sult 2026 · NCT07566156

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

  • Oncology & Hematology Associates of Southwest Virginia, Inc.,DBA Blue Ridge Cancer Care, Blacksburg
  • Virginia Cancer Specialists, PC, Fairfax
  • Oncology & Hematology Associates of Southwest Virginia, Inc.,DBA Blue Ridge Cancer Care, Low Moor
  • agus 4 a bharrachd
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT07421700

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

  • NEXT Oncology Virginia, Fairfax
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT07277413

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  • USO - Virginia Oncology Associates, Norfolk
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT07218380

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

  • Virginia Cancer Specialists, Fairfax
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 10 Sult 2026 · NCT06293898

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

  • University of Virginia Comprehensive Cancer Center, Charlottesville
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 3 Sult 2026 · NCT06774131

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

  • NEXT Virginia, Fairfax
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Sult 2026 · NCT07287995

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

  • Research Site, Norfolk
A’ fastadhÌre 2/3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 20 Lùna 2026 · NCT07129993

A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

  • Clinical Trial Site, Fairfax
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 6 Lùna 2026 · NCT07749586

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  • Virginia Cancer Specialists, Fairfax
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 5 Lùna 2026 · NCT06330064

An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

  • Research Site, Falls Church
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Iuch 2026 · NCT07720284

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

  • Inova Schar Cancer Institute, Fairfax
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Iuch 2026 · NCT04879329

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

  • NEXT Oncology Virginia, Fairfax
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Iuch 2026 · NCT07169734

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

  • The University of Virgina, Charlottesville
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 18 Ògmh 2026 · NCT07484022

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

  • Dren Investigational Site, Fairfax
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 7 Faoi 2026 · NCT06999187

Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC

  • NEXT Oncology, Fairfax
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 24 Samh 2025 · NCT06332755

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Charlottesville
A’ fastadhSgrùdadh amharc
Gach aois · Gach gnè · Air ùrachadh 28 Dàmh 2025 · NCT03452774

A Study of NX-1607 in Adults With Advanced Malignancies

  • University of Virginia, Charlottesville
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 9 Sult 2025 · NCT05107674

Bho ClinicalTrials.gov, dàta air a thogail 5 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.